HTG Molecular Diagnostics Inc (NASDAQ:HTGM) – Equities research analysts at Svb Leerink lifted their Q3 2019 earnings per share (EPS) estimates for shares of HTG Molecular Diagnostics in a research report issued on Tuesday, August 6th. Svb Leerink analyst P. Souda now expects that the medical research company will earn ($0.14) per share for the quarter, up from their prior estimate of ($0.16). Svb Leerink also issued estimates for HTG Molecular Diagnostics’ Q1 2020 earnings at ($0.08) EPS, Q2 2020 earnings at ($0.11) EPS, Q3 2020 earnings at ($0.08) EPS, Q4 2020 earnings at ($0.11) EPS, FY2020 earnings at ($0.39) EPS and FY2021 earnings at ($0.09) EPS.
HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). HTG Molecular Diagnostics had a negative net margin of 79.96% and a negative return on equity of 95.77%. The business had revenue of $5.80 million during the quarter, compared to analysts’ expectations of $5.54 million.
Shares of HTG Molecular Diagnostics stock opened at $1.11 on Friday. The firm has a 50-day simple moving average of $1.50. HTG Molecular Diagnostics has a 52 week low of $1.04 and a 52 week high of $5.46. The stock has a market capitalization of $36.74 million, a P/E ratio of -1.85 and a beta of 1.55. The company has a quick ratio of 6.05, a current ratio of 3.49 and a debt-to-equity ratio of 0.87.
Large investors have recently bought and sold shares of the stock. Perkins Capital Management Inc. lifted its position in shares of HTG Molecular Diagnostics by 37.8% in the first quarter. Perkins Capital Management Inc. now owns 619,920 shares of the medical research company’s stock worth $1,550,000 after buying an additional 169,970 shares in the last quarter. FMR LLC lifted its position in shares of HTG Molecular Diagnostics by 0.6% in the fourth quarter. FMR LLC now owns 3,607,849 shares of the medical research company’s stock worth $9,164,000 after buying an additional 19,804 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of HTG Molecular Diagnostics in the fourth quarter worth about $27,000. BlackRock Inc. lifted its position in shares of HTG Molecular Diagnostics by 16.4% in the fourth quarter. BlackRock Inc. now owns 88,565 shares of the medical research company’s stock worth $225,000 after buying an additional 12,448 shares in the last quarter. Finally, Cowen Prime Services LLC purchased a new stake in shares of HTG Molecular Diagnostics in the first quarter worth about $50,000. Institutional investors own 44.98% of the company’s stock.
HTG Molecular Diagnostics Company Profile
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing.
Featured Article: Federal Reserve
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.